Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects
Open accessThe DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index; 36 of the 59 sources its claims cite were checked for support.
Abstract
Background: There is growing scientific evidence for the therapeutic benefits of the Amazonian plant-based psychedelic “ayahuasca” for neuropsychiatric disorders such as depression and anxiety. However, there are certain challenges when incorporating botanical ayahuasca into biomedical research and clinical therapy environments. Formulations inspired by ayahuasca, which contain specific and standardized active components, are a potential remedy. Methods: We investigated subjective acute and persisting effects of a novel formulation containing the reversible monoamine oxidase inhibitor harmine (orodispersible tablet containing 100 mg MAO-I) and N,N-dimethyltryptamine (incremental intranasal dosing of up to 100 mg DMT), compared with two other conditions, namely harmine alone and placebo, in a crossover RCT in 31 healthy male subjects. Results: DMT + harmine, but not harmine alone, induced a psychedelic experience assessed with the 5D-ASC rating scale [global score: F(2,60) = 80.21, p < 0.001] and acute experience sampling items over time, characterized by psychological insights [PIQ, F(2,58.5) = 28.514, p < 0.001], emotional breakthroughs [EBI, F(2,60) = 26.509, p < 0.001], and low scores on the challenging experience questionnaire [CEQ, F(2,60) = 12.84, p < 0.001]. Participants attributed personal and spiritual significance to the experience (GSR) with mainly positive persisting effects (PEQ) at 1- and 4-months follow-up. Acute drug effects correlated positively with persisting effects. We found no changes in trait measures of personality, psychological flexibility, or general well-being, and no increases in psychopathology (SCL-90-R) were reported. Discussion and Conclusion: Our results suggest that the experience induced by the standardized DMT + harmine formulation induces a phenomenologically rich psychedelic experience, demonstrates good psychological safety and tolerability, is well tolerated, and induces beneficial psychological processes that could possibly support psychotherapy. Further studies are required to investigate the psychotherapeutic potential in patients. Copyright © 2024 Aicher, Mueller, Dornbierer, Suay, Elsner, Wicki, Meling, Caflisch, Hempe, Steinhart, Mueller, Von Rotz, Kleim and Scheidegger.
Overview
CoChat Summary
## TL;DR
This randomized controlled crossover trial in 31 healthy men found that the combined DMT + harmine formulation, but not harmine alone, produced a psychedelic experience with psychological insights, emotional breakthroughs, and mainly positive persisting effects at 1 and 4 months. The study suggests potential psychotherapy-relevant effects and good psychological tolerability, but it was conducted in a non-therapeutic setting and did not show trait changes or increased well-being.
## Key findings
- In 31 healthy male participants, DMT + harmine induced strong acute psychedelic effects on the 5D-ASC global score compared with both harmine and placebo: F(2,60) = 80.21, p < 0.001; all 11 5D-ASC subscales were significantly increased.
- DMT + harmine increased psychological insight and emotional breakthrough: PIQ global score F(2,58.5) = 28.51, p < 0.001; EBI F(2,60) = 26.51, p < 0.001. It also increased challenging experiences relative to the other conditions, but CEQ scores remained low overall.
- Persisting effects at 1 and 4 months were mainly positive across PEQ domains, with significant positive vs negative effects in attitude toward life, mood, social effects, and behavior change (combined follow-up timepoints: r = 0.83, 0.57, 0.46, and 0.78, all p < 0.001).
- No increases were found in trait measures of acceptance/action, cognitive flexibility, nature relatedness, well-being, or openness, and no decreases in neuroticism were found; no increases in psychopathology on the SCL-90-R were reported.
## Methods
- Randomized, double-blind, placebo-controlled crossover trial with three conditions: DMT + harmine (DMT/HAR), harmine only (HAR), and placebo (PLA), separated by at least 2 weeks.
- Sample: 31 healthy male subjects completed all 3 intervention days; 37 were recruited and 6 dropped out. Mean age was 25.39 ± 4.21 years.
- Main analysis used mixed-model ANOVAs for acute/retrospective outcomes, Wilcoxon tests for 2 timepoints, Friedman tests with post-hoc Dunn-Bonferroni tests for 3 timepoints, and correlations between acute and persisting effects.
## Limitations
- The paper states that it did not assess intranasal DMT alone, so the specific pharmacological effects of intranasal DMT remain unclear.
- The authors note that blinding may have been weakened by the psychedelic effects, expectations may have influenced outcomes, and the sample was WEIRD and all male, limiting generalizability.
- The study setting was pharmacologically and neurobehaviorally oriented rather than therapeutic or integration-focused, which the paper says may have reduced introspection and attenuated subjective effects; additionally, only 22 of 31 participants completed all follow-up trait assessments.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
22 Valid · 2 Not valid · 7 Not checked · 99 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“There is growing scientific evidence for the therapeutic benefits of the Amazonian plant-based psychedelic “ayahuasca” for neuropsychiatric disorders such as depression and anxiety.”
§ Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects > Abstract > Background
What the sources say
- Supportedcites [1] Frecska, 2016, The therapeutic potentials of Ayahuasca: possible effects against various diseases of civilization, Front Pharmacol source
The section on mechanisms reports an observed antidepressant effect of ayahuasca. The Psychological and Psychosocial Effects section reports studies finding fewer signs of anxiety among adolescent users and less anxiety in responses to panic-like states, though state- and trait-anxiety measures were unchanged. These findings support the broad claim of growing evidence for potential benefits, not a claim that treatment efficacy for depression or anxiety is established. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [2] Palhano-Fontes, 2014, The therapeutic potentials of Ayahuasca in the treatment of depression source
- Supportedcites [3] Palhano-Fontes, 2019, Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial, Psychol Med source
The Discussion reports that evaluations of regular ayahuasca consumers found reduced anxiety and depressive symptoms compared with non-consumers. The Introduction also describes a prior trial finding reduced depression severity and explains that this paper further tests ayahuasca’s antidepressant effects. Together, these passages support the broad claim of growing evidence, without establishing ayahuasca as a proven treatment for anxiety. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In small clinical pilot studies, ayahuasca has been shown to alleviate symptoms of depression and anxiety (30).”
§ Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects > Introduction
What the sources say
- Supportedcites [30] De Osório, 2015, Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report, Rev Bras Psiquiatr source
The Results report significant reductions in depressive scores and in symptoms on the Anxious-Depression subscale after ayahuasca administration. The Discussion describes the findings as preliminary evidence of antidepressant and anxiolytic effects from a small, uncontrolled study. (LLM, conf=0.90)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Indeed, converging evidence from preclinical and human studies suggest that oral formulations of DMT such as ayahuasca show potential in reducing anxiety, depressive symptoms, addictive behaviors, and posttraumatic distress (1–3, 30–35).”
§ Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects > Introduction
What the sources say
- Partly supportedcites [1] Frecska, 2016, The therapeutic potentials of Ayahuasca: possible effects against various diseases of civilization, Front Pharmacol sourceExperimental — accuracy not yet measured
The Psychological and Psychosocial Effects section reports human observations of less anxiety in some circumstances and possible anti-addictive effects; the addiction-mechanisms section also cites animal experiments on alcohol-related behavior (pages unavailable). But the Discussion presents benefit for PTSD as a hypothesis, not a demonstrated reduction in posttraumatic distress. The copy discusses depression as a possible mechanistic target without reporting reduced depressive symptoms, so the claimed convergence across all four outcomes is not supported. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [2] Palhano-Fontes, 2014, The therapeutic potentials of Ayahuasca in the treatment of depression source
- Partly supportedcites [3] Palhano-Fontes, 2019, Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial, Psychol Med sourceExperimental — accuracy not yet measured
The Results (page unavailable) report lower depression severity after ayahuasca than placebo, and the Discussion reports reduced anxiety and depressive symptoms among regular consumers, alongside animal evidence relevant to antidepressant effects. Our copy does not report evidence that ayahuasca reduces addictive behaviors or posttraumatic distress; its mention of addiction treatment concerns psilocybin, not ayahuasca. (LLM, conf=0.88)
- Partly supportedcites [30] De Osório, 2015, Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report, Rev Bras Psiquiatr sourceExperimental — accuracy not yet measured
The Introduction (page not supplied) describes preclinical evidence of antidepressant potential and reduced panic-related signs, alongside preliminary human evidence for antidepressant effects. The Discussion (page not supplied) also reports antidepressant potential in animals and humans. Our copy does not support the attributed potential to reduce addictive behaviors or posttraumatic distress. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [31] Domínguez-Clavé, 2016, Ayahuasca: pharmacology, neuroscience and therapeutic potential, Brain Res Bull source
- Not checked — no full text of the sourcecites [32] Dos Santos, 2016, The current state of research on ayahuasca: a systematic review of human studies assessing psychiatric symptoms, neuropsychological functioning, and neuroimaging, J Psychopharmacol source
- Partly supportedcites [33] Sarris, 2021, Ayahuasca use and reported effects on depression and anxiety symptoms: an international cross-sectional study of 11,912 consumers, J Affect Disord Rep sourceExperimental — accuracy not yet measured
The Introduction describes human studies reporting antidepressant and anti-addictive effects of ayahuasca, and the Discussion reports self-perceived improvements in anxiety and depression. Our copy does not report a reduction in posttraumatic distress, so it supports only part of the cited sentence. (LLM, conf=0.86)
- Partly supportedcites [34] Van Oorsouw, 2022, Therapeutic effect of an ayahuasca analogue in clinically depressed patients: a longitudinal observational study, Psychopharmacology sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) reports reduced anxiety, depression, and substance use disorder after ayahuasca intake, and the Discussion says this study suggests potential relief of depression and anxiety. Our copy does not report reduced posttraumatic distress, so it does not support that part of the attributed claim. It cites a review of animal and human studies, but does not itself describe converging preclinical findings across all four outcomes. (LLM, conf=0.87)
- Partly supportedcites [35] Zeifman, 2019, The impact of Ayahuasca on suicidality: results from a randomized controlled trial, Front Pharmacol sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports decreases in non-suicide-related depressive symptoms after ayahuasca and cites prior research on improvements in depression. The paper does not establish the full attributed range of benefits: its trial assessed suicidality in people with treatment-resistant depression, not reductions in anxiety, addictive behaviors, or posttraumatic distress. (LLM, conf=0.86)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Additionally, ayahuasca brew batches have varying levels and ratios of alkaloids due to different recipes including differences in plant combinations and ratios, variations in cooking duration and method, and naturally varying alkaloid levels in the plants used, which complicates the creation of standardized dosing protocols (6, 50).”
§ Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects > Introduction
What the sources say
- Not checked — no full text of the sourcecites [6] Kaasik, 2021, Chemical composition of traditional and analog Ayahuasca, J Psychoactive Drugs source
- Partly supportedcites [50] Rodríguez, 2022, New insights into the chemical composition of Ayahuasca, ACS Omega sourceExperimental — accuracy not yet measured
The Introduction says alkaloid quantities vary with the plant varieties and species used, and Results and Discussion (Quantitative Analysis of Alkaloids; page unavailable) reports differing concentrations and ratios across samples, possibly reflecting different amounts of plants in the preparations. The cited paper does not establish that cooking duration or method causes this variation, or explicitly connect the variation to difficulties creating standardized dosing protocols. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The MAO-Is prevent the degradation of the N,N-dimethyltryptamine (DMT) contained in the Psychotria viridis leaves or other additional plants, thereby DMT becomes orally bioavailable (7–9).”
§ Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects > Introduction
What the sources say
- Not checked — no full text of the sourcecites [7] Callaway, 1996, Quantitation of N,N-dimethyltryptamine and Harmala alkaloids in human plasma after Oral dosing with Ayahuasca, J Anal Toxicol source
- Supportedcites [8] Barker, 2022, Administration of NN-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMT, Psychopharmacology source
In “Ayahuasca as a source of DMT in psychedelic therapeutics” (page unavailable), the paper says DMT from Psychotria leaves is not orally active alone but becomes active when combined with harmala MAO inhibitors. The same section says those inhibitors protect DMT from metabolic degradation. (LLM, conf=0.95)
- Supportedcites [9] Carbonaro, 2016, Neuropharmacology of N,N-dimethyltryptamine, Brain Res Bull source
Section 2.3, “Bioavailability of exogenous DMT,” says that DMT is not orally active because peripheral MAO rapidly degrades it, and that oral formulations contain MAO inhibitors to make DMT bioavailable. This supports the mechanism attributed to the source. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
46 more claims · 3 with their cited sources checked
Create a free account to see all 130 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 58
- Probably not a substantial claim. 28
Statistics that don’t add up
Each reported p-value recomputed from its test statistic and degrees of freedom.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“F(2, 60) = 3.94, p = 0.023”
§ Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects > Results > Post-acute retrospective description of the acute subjective drug effects
Reported p = .023 · recomputed p = .025
Statistics recomputed
Every reported test result, recomputed from its test statistic and degrees of freedom. A result shows as not adding up only once an independent check has confirmed it.
- Doesn’t add upF(2, 60) = 3.94reported p = .023 · recomputed p = .025
“F(2, 60) = 3.94, p = .023”
- ConsistentF(2, 60) = 80.21reported p < .001 · recomputed p < .001
“F(2,60) = 80.21, p < .001”
- ConsistentF(2, 58.5) = 28.514reported p < .001 · recomputed p < .001
“F(2,58.5) = 28.514, p < .001”
- ConsistentF(2, 60) = 26.509reported p < .001 · recomputed p < .001
“F(2,60) = 26.509, p < .001”
- ConsistentF(2, 60) = 12.84reported p < .001 · recomputed p < .001
“F(2,60) = 12.84, p < .001”
27 more recomputed tests
Create a free account to see every test the Stats check recomputed.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects > Materials and methods > Outcome measures
“Its global score consists of 26-items forming seven subscales: Fear, grief, physical distress, insanity, isolation, death, paranoia; and a global score.”
§ Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects > Results > Post-acute retrospective description of the acute subjective drug effects
“There was a significant drug effect on the CEQ global score [F(2, 60) = 12.84, p < 0.001] and most subscales [fear: F(2, 60) = 5.09, p = 0.009; grief: F(2, 60) = 4.28, p = 0.018; physical distress: F(2, 60) = 14.01, p < 0.001; insanity: F(2, 60) = 7.86, p < 0.001; death: F(2, 60) = 3.94, p = 0.023], but not for the subscales insolation [F(2, 60) = 1.86, p = 0.165] and paranoia [F(2, 60) = 1.97, p = 0.15].”
Citations
Cites
The weirdest people in the world?
Henrich, J., Heine, S. J., & Norenzayan, A. (2010) · Behavioral and Brain Sciences · doi:10.1017/s0140525x0999152x · Cited by 12,641
The WHO-5 well-being index: A systematic review of the literature
Topp, C. W., Østergaard, S. D., Søndergaard, S., & Bech, P. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000376585 · Cited by 4,708
Bond, F. W., Hayes, S. C., Baer, R. A., Carpenter, K. M., Guenole, N., Orcutt, H. K., Waltz, T., & Zettle, R. D. (2011) · Behavior Therapy · doi:10.1016/j.beth.2011.03.007 · Cited by 3,950
The international personality item pool and the future of public-domain personality measures
Goldberg, L. R., Johnson, J. A., Eber, H. W., Hogan, R., Ashton, M. C., Cloninger, C. R., & Gough, H. G. (2006) · Journal of Research in Personality · doi:10.1016/j.jrp.2005.08.007 · Cited by 3,185
Garnefski, N., Kraaij, V., Schroevers, M. J., & Somsen, G. A. (2008) · Journal of Clinical Psychology in Medical Settings · doi:10.1007/s10880-008-9136-5 · Cited by 2,479
Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050045 · Cited by 2,442
The SCL-90 and the MMPI: A Step in the Validation of a New Self-Report Scale
Derogatis, L. R., Rickels, K., & Rock, A. F. (1976) · British Journal of Psychiatry · doi:10.1192/bjp.128.3.280 · Cited by 2,298 · cited 1×
“The Symptom Check-List-90-Revised [SCL-90-R (58, 59)”
Nisbet, E. K., Zelenski, J. M., & Murphy, S. A. (2009) · Environment and Behavior · doi:10.1177/0013916508318748 · Cited by 1,963
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684
Human hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
Dennis, J. P., & Vander Wal, J. S. (2010) · Cognitive Therapy and Research · doi:10.1007/s10608-009-9276-4 · Cited by 1,118
MacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111420188 · Cited by 895 · cited 1×
“…selection bias remains, as studies including treatments with psychedelic substances require a rather high degree of motivation and openness to experience (82) by the participants because of the time-demanding study procedure and the phenomenologically rich nature of psychedelic experiences.”
BackgroundPalhano-Fontes, F., Barreto, D., Onias, H., Andrade, K. C., Novaes, M. M., Pessoa, J. A., Mota-Rolim, S. A., Osório, F. L., Sanches, R., dos Santos, R. G., et al. (2019) · Psychological Medicine · doi:10.1017/s0033291718001356 · Cited by 852
Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression
aan het Rot, M., Collins, K. A., Murrough, J. W., Perez, A. M., Reich, D. L., Charney, D. S., & Mathew, S. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.038 · Cited by 690
Psychometric evaluation of the altered states of consciousness rating scale (OAV)
Studerus, E., Gamma, A., & Vollenweider, F. X. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012412 · Cited by 683
Psychedelics and the essential importance of context
Carhart-Harris, R. L., Roseman, L., Haijen, E., Erritzoe, D., Watts, R., Branchi, I., & Kaelen, M. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118754710 · Cited by 657 · cited 1×
“Contextual factors, such as the environment in which the experience takes place (setting), the mindset of the individual (set), and the support available after the experience (integration and setting), have a huge impact on the effects of psychedelics (85–88).”
BackgroundPsychedelics and Psychedelic-Assisted Psychotherapy
Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I., Kalin, N. H., McDonald, W. M., & and the Work Group on Biomarkers and Novel Treatments, A. D. O. T. A. P. A. C. O. R. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19010035 · Cited by 649
The Standardized Psychometric Assessment of Altered States of Consciousness (ASCs) in Humans
Dittrich, A. (1998) · Pharmacopsychiatry · doi:10.1055/s-2007-979351 · Cited by 577
Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors
Vargas, M. V., Dunlap, L. E., Dong, C., Carter, S. J., Tombari, R. J., Jami, S. A., Cameron, L. P., Patel, S. D., Hennessey, J. J., Saeger, H. N., et al. (2023) · Science · doi:10.1126/science.adf0435 · Cited by 489 · cited 1×
“…serotonin and has agonistic properties at a variety of serotonin receptors (mainly 5-HT2A, 5-HT2C, 5-HT1A), but also glutamate, dopamine, acetylcholine, sigma-1, and trace amine-associated receptors (9–12), similar to other psychedelics such as psilocybin or lysergic acid diethylamide (LSD) (13).”
BackgroundOsório, F. D. L., Sanches, R. F., Macedo, L. R., dos Santos, R. G., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A., & Hallak, J. E. (2015) · Revista Brasileira de Psiquiatria · doi:10.1590/1516-4446-2014-1496 · Cited by 488
Hartogsohn, I. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116677852 · Cited by 483
Sanches, R. F., de Lima Osório, F., dos Santos, R. G., Macedo, L. R. H., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A. S., & Hallak, J. E. C. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000436 · Cited by 466
The pharmacology of psilocybin
Passie, T., Seifert, J., Schneider, U., & Emrich, H. M. (2002) · Addiction Biology · doi:10.1080/1355621021000005937 · Cited by 465 · cited 2×
“Both LSD and psilocybin show rapid tolerance at serotonergic receptors (13, 39), which can be a disadvantage for clinical application (40) and makes them less suited for repeated clinical dosing regimens.”
BackgroundInfluentialThe pharmacology of lysergic acid diethylamide: A review
Passie, T., Halpern, J. H., Stichtenoth, D. O., Emrich, H. M., & Hintzen, A. (2008) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2008.00059.x · Cited by 455
Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory
Roseman, L., Haijen, E., Idialu-Ikato, K., Kaelen, M., Watts, R., & Carhart-Harris, R. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119855974 · Cited by 413
Riba, J., Valle, M., Urbano, G., Yritia, M., Morte, A., & Barbanoj, M. J. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.049882 · Cited by 390
Barrett, F. S., Bradstreet, M. P., Leoutsakos, J.-M. S., Johnson, M. W., & Griffiths, R. R. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116678781 · Cited by 366
Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil.
GROB, C. S., McKENNA, D. J., CALLAWAY, J. C., BRITO, G. S., NEVES, E. S., OBERLAENDER, G., SAIDE, O. L., LABIGALINI, E., TACLA, C., MIRANDA, C. T., et al. (1996) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-199602000-00004 · Cited by 338
Blinding and expectancy confounds in psychedelic randomized controlled trials
Muthukumaraswamy, S. D., Forsyth, A., & Lumley, T. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1933434 · Cited by 324
Neural correlates of the DMT experience assessed with multivariate EEG
Timmermann, C., Roseman, L., Schartner, M., Milliere, R., Williams, L. T. J., Erritzoe, D., Muthukumaraswamy, S., Ashton, M., Bendrioua, A., Kaur, O., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-51974-4 · Cited by 315 · cited 1×
“While other studies investigating psychedelics often include participants with previous psychedelic experience (17, 18), we excluded participants more than 15 lifetime psychedelic experiences resulting in a sample with no or only little previous psychedelic experience.”
BackgroundRiba, J., Rodríguez-Fornells, A., Urbano, G., Morte, A., Antonijoan, R., Montero, M., Callaway, J. C., & Barbanoj, M. J. (2001) · Psychopharmacology · doi:10.1007/s002130000606 · Cited by 303
The paradoxical psychological effects of lysergic acid diethylamide LSD
Carhart-Harris, R. L., Kaelen, M., Bolstridge, M., Williams, T. M., Williams, L. T., Underwood, R., Feilding, A., & Nutt, D. J. (2016) · Psychological Medicine · doi:10.1017/s0033291715002901 · Cited by 293
Strassman, R. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950020009001 · Cited by 291
Neuropharmacology of N,N-dimethyltryptamine
Carbonaro, T. M., & Gatch, M. B. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.04.016 · Cited by 268 · cited 2×
“The MAO-Is prevent the degradation of the N,N-dimethyltryptamine (DMT) contained in the Psychotria viridis leaves or other additional plants, thereby DMT becomes orally bioavailable (7–9).”
BackgroundEffects of psilocybin therapy on personality structure
Erritzoe, D., Roseman, L., Nour, M. M., MacLean, K., Kaelen, M., Nutt, D. J., & Carhart‐Harris, R. L. (2018) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12904 · Cited by 267
Ketamine abuse potential and use disorder
Liu, Y., Lin, D., Wu, B., & Zhou, W. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.05.016 · Cited by 256 · cited 1×
“Although repeated administration of ketamine was shown to sustain antidepressant effects (41, 42), chronic ketamine use puts patients at risk due to its addictive properties and some long-term toxicity (43).”
BackgroundThe therapeutic potentials of Ayahuasca: possible effects against various diseases of civilization
Frecska, E., Bokor, P., & Winkelman, M. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00035 · Cited by 242
Long-lasting subjective effects of LSD in normal subjects.
Schmid, Y., & Liechti, M. E. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4733-3 · Cited by 232
The antipodes Of the mind: Charting the Phenomenology of the Ayahuasca Experience
Shanon, B. (2002) · doi:10.1093/oso/9780199252923.001.0001 · Cited by 232
Assessment of addiction severity among ritual users of ayahuasca.
Fábregas, J. M., González, D., Fondevila, S., Cutchet, M., Fernández, X., Barbosa, P. C. R., Alcázar-Córcoles, M. Á., Barbanoj, M. J., Riba, J., & Bouso, J. C. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.03.024 · Cited by 227
Ayahuasca: pharmacology, neuroscience and therapeutic potential
Domínguez-Clavé, E., Soler, J., Elices, M., Pascual, J. C., Álvarez, E., de la Fuente Revenga, M., Friedlander, P., Feilding, A., & Riba, J. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.03.002 · Cited by 226
Holze, F., Ley, L., Müller, F., Becker, A. M., Straumann, I., Vizeli, P., Kuehne, S. S., Roder, M. A., Duthaler, U., Kolaczynska, K. E., et al. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01297-2 · Cited by 226
The globalization of ayahuasca: harm reduction or benefit maximization?
Tupper, K. W. (2008) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2006.11.001 · Cited by 212 · cited 1×
“Scientific interest in the N,N-dimethyltryptamine (DMT) containing Amazonian psychedelic “ayahuasca” has increased due to its potential therapeutic benefits (1–3) and its increasingly globalized use (4).”
BackgroundMatveychuk, D., Thomas, R. K., Swainson, J., Khullar, A., MacKay, M.-A., Baker, G. B., & Dursun, S. M. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320916657 · Cited by 209
Garcia-Romeu, A., & Richards, W. A. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1486289 · Cited by 189 · cited 1×
“…increased awareness, introspection and self-reflection, dream-like visions, recollection of personal memories, and intensified emotions (10, 11, 20), potentially leading to deep psychological and existential insights (21), which might promote the efficacy of psychotherapeutic interventions (22–25).”
BackgroundHamill, J., Hallak, J., Dursun, S. M., & Baker, G. (2019) · Current Neuropharmacology · doi:10.2174/1570159x16666180125095902 · Cited by 178
Psychedelic integration: an analysis of the concept and its practice
Bathje, G. J., Majeski, E., & Kudowor, M. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.824077 · Cited by 174 · cited 1×
“Due to the potential of psychedelics to elicit profound psychological and emotional responses, providing empathetic support during and after a psychedelic experience represents a fundamental ethical requirement (84, 89).”
BackgroundDavis, A. K., Barrett, F. S., So, S., Gukasyan, N., Swift, T. C., & Griffiths, R. R. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120967878 · Cited by 169
Callaway, J. C., Raymon, L. P., Hearn, W. L., McKenna, D. J., Grob, C. S., Brito, G. S., & Mash, D. C. (1996) · Journal of Analytical Toxicology · doi:10.1093/jat/20.6.492 · Cited by 160
Dambrun, M. (2016) · Consciousness and Cognition · doi:10.1016/j.concog.2016.09.013 · Cited by 151
Munkholm, K., Paludan-Müller, A. S., & Boesen, K. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-024886 · Cited by 151
Celidwen, Y., Redvers, N., Githaiga, C., Calambás, J., Añaños, K., Chindoy, M. E., Vitale, R., Rojas, J. N., Mondragón, D., Rosalío, Y. V., et al. (2023) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2022.100410 · Cited by 142
Pharmacology of ayahuasca administered in two repeated doses
dos Santos, R. G., Grasa, E., Valle, M., Ballester, M. R., Bouso, J. C., Nomdedéu, J. F., Homs, R., Barbanoj, M. J., & Riba, J. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2434-x · Cited by 141
Eisner, B. (1997) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1997.10400190 · Cited by 135
Ley, L., Holze, F., Arikci, D., Becker, A. M., Straumann, I., Klaiber, A., Coviello, F., Dierbach, S., Thomann, J., Duthaler, U., et al. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01607-2 · Cited by 130
dos Santos, R. G., Balthazar, F. M., Bouso, J. C., & Hallak, J. E. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116652578 · Cited by 125
Adverse effects of ayahuasca: Results from the Global Ayahuasca Survey
Bouso, J. C., Andión, Ó., Sarris, J. J., Scheidegger, M., Tófoli, L. F., Opaleye, E. S., Schubert, V., & Perkins, D. (2022) · PLOS Global Public Health · doi:10.1371/journal.pgph.0000438 · Cited by 118 · cited 3×
“…DMT varies greatly between and within individuals due to the excessive metabolic first-pass degradation by the MAO enzyme associated with oral ingestion of ayahuasca, which potentially leads to unexpected intensities, overwhelming experiences, and thereby increases psychological risks (48).”
BackgroundInfluentialSelf-citationBrito-da-Costa, A. M., Dias-da-Silva, D., Gomes, N. G. M., Dinis-Oliveira, R. J., & Madureira-Carvalho, Á. (2020) · Pharmaceuticals · doi:10.3390/ph13110334 · Cited by 117
Health status of ayahuasca users
Barbosa, P. C. R., Mizumoto, S., Bogenschutz, M. P., & Strassman, R. J. (2012) · Drug Testing and Analysis · doi:10.1002/dta.1383 · Cited by 112
Uthaug, M. V., Mason, N. L., Toennes, S. W., Reckweg, J. T., de Sousa Fernandes Perna, E. B., Kuypers, K. P. C., van Oorsouw, K., Riba, J., & Ramaekers, J. G. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05817-8 · Cited by 112
TUPPER, K. W. (2009) · Global Networks · doi:10.1111/j.1471-0374.2009.00245.x · Cited by 110 · cited 1×
“This plant-based brew has been used by Indigenous cultures for centuries for ceremonial and medicinal purposes (5).”
BackgroundExperiences of encounters with Ayahuasca–“the vine of the soul”
Kjellgren, A., Eriksson, A., & Norlander, T. (2009) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2009.10399767 · Cited by 97
Set and setting: a randomized study of different musical genres in supporting psychedelic therapy
Strickland, J. C., Garcia-Romeu, A., & Johnson, M. W. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00187 · Cited by 97
Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants
Vogt, S. B., Ley, L., Erne, L., Straumann, I., Becker, A. M., Klaiber, A., Holze, F., Vandersmissen, A., Mueller, L., Duthaler, U., et al. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02477-4 · Cited by 89
Effect of some indolealkylamines on man
TURNER, W. J. (1959) · Archives of Neurology And Psychiatry · doi:10.1001/archneurpsyc.1959.02340130141020 · Cited by 88 · cited 2×
“It is noteworthy to mention that Turner and Merlis conducted a study in the 1950s wherein they found intranasal DMT to be pharmacologically inactive (54).”
BackgroundThe impact of Ayahuasca on suicidality: results from a randomized controlled trial
Zeifman, R. J., Palhano-Fontes, F., Hallak, J., Arcoverde, E., Maia-Oliveira, J. P., & Araujo, D. B. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01325 · Cited by 87 · cited 1×
“Indeed, converging evidence from preclinical and human studies suggest that oral formulations of DMT such as ayahuasca show potential in reducing anxiety, depressive symptoms, addictive behaviors, and posttraumatic distress (1–3 , 30– 35).”
BackgroundPhenomenology and content of the inhaled N, N-dimethyltryptamine (N, N-DMT) experience
Lawrence, D. W., Carhart-Harris, R. L., Griffiths, R. R., & Timmermann, C. (2022) · Scientific Reports · doi:10.1038/s41598-022-11999-8 · Cited by 86
van Oorsouw, K., Toennes, S. W., & Ramaekers, J. G. (2022) · Psychopharmacology · doi:10.1007/s00213-021-06046-9 · Cited by 74
Sarris, J., Perkins, D., Cribb, L., Schubert, V., Opaleye, E., Bouso, J. C., Scheidegger, M., Aicher, H., Simonova, H., Horák, M., et al. (2021) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2021.100098 · Cited by 73
Self-citationPsychedelics and psychotherapy
Nayak, S., & Johnson, M. W. (2021) · Pharmacopsychiatry · doi:10.1055/a-1312-7297 · Cited by 71
Psychological and physiological effects of extended DMT
Luan, L. X., Eckernäs, E., Ashton, M., Rosas, F. E., Uthaug, M. V., Bartha, A., Jagger, S., Perai, K. G., Gomes, L., Nutt, D. J., et al. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231196877 · Cited by 66
Catharsis in psychotherapy: A new perspective
Nichols, M. P., & Efran, J. S. (1985) · Psychotherapy: Theory, Research, Practice, Training · doi:10.1037/h0088525 · Cited by 64 · cited 2×
“This combination represents a potential for transformative psychological processes and has been discussed to be essential for the improvement of mental health (28, 29).”
BackgroundInfluentialChemical composition of traditional and analog Ayahuasca
Kaasik, H., Souza, R. C. Z., Zandonadi, F. S., Tófoli, L. F., & Sussulini, A. (2021) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2020.1815911 · Cited by 59
Barker, S. A. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06065-0 · Cited by 58
Drug tolerance: a known unknown in translational neuroscience
Bespalov, A., Müller, R., Relo, A.-L., & Hudzik, T. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.01.008 · Cited by 50 · cited 1×
“Both LSD and psilocybin show rapid tolerance at serotonergic receptors (13, 39), which can be a disadvantage for clinical application (40) and makes them less suited for repeated clinical dosing regimens.”
BackgroundDurante, Í., dos Santos, R. G., Bouso, J. C., & Hallak, J. E. (2021) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2020-0913 · Cited by 49 · cited 1×
“Even though observational data suggest that the risk of combining short-acting, reversible MAO-I such as in ayahuasca with antidepressants might be overestimated (79), more research is needed to fully understand the interactions and potential associated risks.”
BackgroundAyahuasca as Antidepressant? Psychedelics and Styles of Reasoning in Psychiatry
Anderson, B. T. (2012) · Anthropology of Consciousness · doi:10.1111/j.1556-3537.2012.01056.x · Cited by 43
Wolff, T. J., Ruffell, S., Netzband, N., & Passie, T. (2019) · Journal of Psychedelic Studies · doi:10.1556/2054.2019.007 · Cited by 40 · cited 4×
“The clear biphasic phenomenology of initially psychedelic and potentially overwhelming, and subsequently more empathogenic experiences, described for ayahuasca such as discussed by Wolff (19, 49) as “ bottleneck ” phenomenon during the ayahuasca experience was less prominent in our study.”
BackgroundInfluentialThe therapeutic potentials of Ayahuasca in the treatment of depression
Palhano-Fontes, F., Alchieri, J. C., Oliveira, J. P. M., Soares, B. L., Hallak, J. E. C., Galvao-Coelho, N., & de Araujo, D. B. (2014) · The Therapeutic Use of Ayahuasca · doi:10.1007/978-3-642-40426-9_2 · Cited by 36
Systematic review of psychometric instruments used in research with psychedelics
de Deus Pontual, A. A., Senhorini, H. G., Corradi-Webster, C. M., Tófoli, L. F., & Daldegan-Bueno, D. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2079108 · Cited by 36
Dornbierer, D. A., Marten, L., Mueller, J., Aicher, H. D., Mueller, M. J., Boxler, M., Kometer, M., Kosanic, D., von Rotz, R., Puchkov, M., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1246892 · Cited by 32
Self-citationNew insights into the chemical composition of Ayahuasca
Rodríguez, L., López, A., Moyna, G., Seoane, G. A., Davyt, D., Vázquez, Á., Hernández, G., & Carrera, I. (2022) · ACS Omega · doi:10.1021/acsomega.2c00795 · Cited by 30
Gasser, P. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2021_268 · Cited by 29
Scheidegger, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-55688-4_3 · Cited by 23
Self-citationBlinding and expectancy confounds in psychedelic randomised controlled trials
Muthukumaraswamy, S., Forsyth, A., & Lumley, T. (2021) · doi:10.31234/osf.io/q2hzm · Cited by 15
Catharsis as a therapy: an overview on health and human development
Bukar, A., Abdullah, A., Opara, J. A., M, A., & Hassan, A. (2019) · Journal of Physical Health and Sports Medicine · doi:10.36811/jphsm.2019.110007 · Cited by 9 · cited 2×
“This combination represents a potential for transformative psychological processes and has been discussed to be essential for the improvement of mental health (28, 29).”
BackgroundCarbonaro, T. M., Barrett, F. S., Bradstreet, M. P., Johnson, M. W., MacLean, K. A., Jesse, R., & Griffiths, R. R. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.09.118 · Cited by 3
The internationalisation of ayahuasca, edited by Beatriz C. Lebate and Henrik Jungaberle
Aldridge, J. A. (2013) · Drugs Education Prevention and Policy · doi:10.3109/09687637.2013.812447 · Cited by 1 · cited 1×
“The overuse of plants contained in ayahuasca is another consequence of ayahuasca tourism and plant export, that come along with the globalization of ayahuasca (53).”
Background
Research works printed but not linked: 3
- Franke, 2002, SCL-90-R: Symptom-Checkliste von L.R. Derogatis: Deutsche Version
- 2021, R: A language and environment for statistical computing
- 2022, World mental health report
Cited by
Psychedelics in neuroinflammation: Mechanisms and therapeutic potential
de Deus, J. L., Maia, J. M., Soriano, R. N., Amorim, M. R., & Branco, L. G. S. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111278 · Cited by 40
Benefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression
Ramaekers, J. G., Reckweg, J. T., & Mason, N. L. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230890 · Cited by 37
Insights on psychedelics: A systematic review of therapeutic effects
Kugel, J., Laukkonen, R., Yaden, D. B., Yücel, M., & Liknaitzky, P. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106117 · Cited by 32
A Phase 1 single ascending dose study of pure oral harmine in healthy volunteers
Ables, J. L., Israel, L., Wood, O., Govindarajulu, U., Fremont, R., Banerjee, R., Liu, H.-T., Cohen, J., Wang, P., Kumar, K., et al. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241273772 · Cited by 18
Meling, D., Egger, K., Aicher, H., Redondo, J. J., Mueller, J., Dornbierer, J., Temperli, E., Vasella, E. A., Caflisch, L., Pfeiffer, D., et al. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241282637 · Cited by 24
“…the previous evidence of emotional breakthrough experiences occasioned by a variety of psyche-delics (Roseman et al., 2019), including DMT-harmine (Aicher et al., 2024), our results represent a direct demonstration of a significantly greater increase in emotional breakthrough in meditation…”
BackgroundResultSelf-citation
Metadata
- Authors
- Aicher, H. D., Mueller, M. J., Dornbierer, D. A., Suay, D., Elsner, C., Wicki, I., Meling, D., Caflisch, L., Hempe, A., Steinhart, C., Mueller, J., Von Rotz, R., Kleim, B., & Scheidegger, M.
- Affiliations
- University of Zurich (CH)
- IMT School for Advanced Studies Lucca (IT)
- University of Freiburg (DE)
- Corresponding author
- Aicher, Helena D.
- ORCID
- Venue
- Frontiers in Psychiatry
- Publisher
- Frontiers Media SA
- Published
- 2024-01-08
- Volume
- 14
- Pages
- 1302559-1302559
- ISSN
- 1664-0640 (ISSN-L)
- PMC
- PMC10804806
- OpenAlex
- W4390825728
- Cited by
- 33
- References
- 89
- Citations by year
- 2026: 7 · 2025: 18 · 2024: 8
- FWCI
- 16.48
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Psychiatry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- OSF Preprints (OSF Preprints) (submittedVersion)
- Repository for Publications and Research Data (ETH Zurich) (submittedVersion, cc-by)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by)
- ETH Zürich Research Collection
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (191935)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Physical Sciences › Chemistry › Organic Chemistry › Synthesis and bioactivity of alkaloids
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Alkaloids: synthesis and pharmacology
- Keywords
- N,N-dimethyltryptamine, harmine, monoamine oxidase inhibitors, psychedelic experience, psychological safety, psychological flexibility, psychological well-being, psychological insight, spiritual meaning, depression, anxiety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.